Home/Pipeline/Prototype/Lead Candidate 2

Prototype/Lead Candidate 2

Oncology (unspecified)

Pre-clinicalActive

Key Facts

Indication

Oncology (unspecified)

Phase

Pre-clinical

Status

Active

Company

OncoQR ML

About OncoQR ML

OncoQR ML is an Austrian pre-clinical biotech startup focused on next-generation cancer immunotherapies. The company's vision is to defeat cancer by activating all four of the immune system's natural tumor-killing mechanisms in parallel through its Active Checkpoint Control Immunotherapy (ACCI) approach. Its foundational S-TIR™ technology platform, in-licensed from S-TARget therapeutics GmbH, serves as the basis for therapeutic cancer vaccines and is offered for out-licensing on a target-by-target basis. The company has achieved in vivo proof-of-concept for two lead candidates and is led by senior pharma professionals with extensive R&D and management experience.

View full company profile

Therapeutic Areas

Oncology

Other Oncology (unspecified) Drugs

Drug	Company	Phase	Status
Oncology Vaccine Program	CHAIN Biotech	Pre-clinical	Active
ARX305	NovoCodex Biopharmaceuticals	Phase 1	Active
ARX788	NovoCodex Biopharmaceuticals	Phase 1	Active
Cancer Immunotherapy Nanotherapeutic	Flashpoint Therapeutics	Phase 1	Active
GRWD5769	Greywolf Therapeutics	Phase 1/2	Active
Platform-derived Program(s)	Immuto Scientific	Discovery/Pre-clinical	Active
MBT Oncology Program	Ionic Pharmaceuticals	Pre-clinical	Active
ISB 2301	Ichnos Glenmark Innovation	Preclinical	Active
GRC 65327	Ichnos Glenmark Innovation	Preclinical	Active
Platform-Derived Pipeline	Phinomics	Discovery/Pre-clinical	Active
Lead Small-Molecule Inhibitor	Eris Biotech	Pre-clinical	Active
Orotecan™	Edison Oncology	Phase 1/2a	Active